Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
Patients showing tumour progression while receiving [<sup>177</sup>Lu]Lu-PSMA-I&T radioligand therapy may benefit from rescue therapy with the novel radiohybrid PSMA ligand, [<sup>177</sup>Lu]Lu-rhPSMA-10.1. Higher tumour absorbed radiation doses with [<sup>177</sup>Lu]Lu-rhPSMA-10.1 may overcome primary and acquired radiation resistance.
Authors
- Ralph A. Bundschuh (ORCID: https://orcid.org/0000-0001-7291-9372)
- H. Kempter
- Alexander Gäble (ORCID: https://orcid.org/0000-0002-0910-2981)
- Kazuhito Fukushima
- Martin Trepel
- Andreas Rinscheid (ORCID: https://orcid.org/0009-0008-8625-0217)
- Tilman Janzen
- Dorothea Weckermann
- Georgine Wienand
- Marianne Patt (ORCID: https://orcid.org/0000-0001-9696-4477)
- Malte Kircher (ORCID: https://orcid.org/0000-0003-4355-0881)
- Johanna S. Enke (ORCID: https://orcid.org/0000-0002-2690-8856)
- Ana Nikolić (ORCID: https://orcid.org/0000-0003-3145-4032)
- Julie Steinestel
- Constantin Lapa (ORCID: https://orcid.org/0000-0001-7536-2207)
- Christian H. Pfob (ORCID: https://orcid.org/0000-0003-2989-5883)
- Alexander Dierks
Institutions
- Kobe International University (JP)
- Technische Hochschule Augsburg (DE)
- University of Augsburg (DE)
- University Hospital Augsburg (DE)
- BUND Naturschutz (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1007/s00259-024-06959-5
- Citations
- 8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.35